Navigation Links
Aspirin May Protect Against Colorectal Cancer -- But Only in Certain People

FRIDAY, March 11 (HealthDay News) -- Taking aspirin to protect against colorectal cancer may be effective, but mostly in people at increased risk for the disease due to elevated levels of an inflammatory biomarker in their blood, according to a new study.

Previous research has found that people who take aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs) have a reduced risk of colorectal cancer. Other studies have noted that inflammation contributes to the development of conditions such as cardiovascular disease and several types of cancer.

In this new study, researchers at Massachusetts General Hospital and the Dana-Farber Cancer Institute found that elevated baseline levels of an inflammatory marker called "soluble tumor necrosis factor receptor-2 (sTNFR-2)" were associated with increased risk of colorectal cancer and also predicted who might benefit from taking aspirin or other NSAIDs, such as ibuprofen or naproxen.

The researchers analyzed data from 280 participants in the Nurses' Health Study who were cancer-free when they provided a blood sample in 1989 and 1990, but developed colorectal cancer over the next 14 years. These patients were compared to 555 age-matched participants who did not develop colorectal cancer.

The researchers analyzed baseline levels of three inflammatory markers -- sTNFR-2, c-reactive protein (CRP), and interleukin-6 (IL-6). There was no association between levels of CRP or IL-6 and risk of developing colorectal cancer. But people with the highest levels of sTNFR-2 were 60 percent more likely to develop colorectal cancer than those with the lowest levels of the factor.

The researchers also found that the reduced risk of colorectal cancer associated with regular use of aspirin or other NSAIDs was primarily seen among people with high baseline levels of sTNFR-2.

The study appears in the March issue of the journal Gastroenterology.

"These findings suggest that a blood biomarker may be helpful in deciding whether individuals should take aspirin or NSAIDs to reduce their cancer risk," lead author Dr. Andrew Chan, of the gastrointestinal unit at Massachusetts General Hospital, said in a hospital news release.

"They also indicate that chronic inflammatory pathways are quite complex, and further studies are needed to understand which facets of the inflammatory response are most associated with the development of colorectal cancer," he added.

More information

The U.S. National Cancer Institute has more about colorectal cancer prevention.

-- Robert Preidt

SOURCE: Massachusetts General Hospital, Dana-Farber Cancer Institute, news release, March 9, 2011

Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Aspirins ability to protect against colorectal cancer may depend on inflammatory pathways
2. Small bowel blood flow in healthy subjects receiving low-dose aspirin
3. Low-Dose Aspirin Boosts Accuracy of Colon Cancer Test
4. Low-dose aspirin reduces death rates from range of cancers by between 20 and 30 percent
5. Daily Aspirin Linked to Steep Drop in Cancer Risk
6. Bleeding Risk With Plavix-Aspirin Regimen May Be Serious
7. Aspirin May Help Patients Beat Prostate Cancer
8. Aspirin, Statins May Reduce Problems After Heart Surgery
9. IV Aspirin Drip Appears to Be Safe, Effective for Migraine
10. Low-Dose Aspirin May Reduce Colon Cancer Risk
11. Can aspirin prolong a healthy life?
Post Your Comments:
Related Image:
Aspirin May Protect Against Colorectal Cancer -- But Only in Certain People
(Date:6/24/2016)... Rhinebeck, NY (PRWEB) , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of ... of companies that call for a minimum wage raise to $12 an hour by 2020 ... wage. This will restore the lost value of the minimum wage, assure the wage floor ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB ... Decision Making in Emergency Medicine conference in Ponte Vedra Beach, FL. The awards ... in Emergency Medicine Practice and Pediatric Emergency Medicine Practice. , “With ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® & Innovative ... has initiated cultivation and processing operations at its production facility, and opened its ... Puradigm is the manufacturer of a complete system of proactive air and surface ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... National recruitment ... a life sciences executive with extensive sequencing and genomics experience, as Vice President of ... position, Ms. Hill will be responsible for leading the sales team in the commercialization ...
(Date:6/24/2016)... Gaithersburg, MD (PRWEB) , ... June 24, 2016 ... ... and protocols for human induced pluripotent stem (iPS) cells and other difficult to ... PluriQ™ G9™ Cloning Medium. The PluriQ™ G9™ Gene Editing System is ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... SOUTH SAN FRANCISCO, Calif. , June 24, ... GBT ), a biopharmaceutical company developing novel ... with significant unmet needs, today announced the closing ... 6,400,000 shares of common stock, at the public ... the shares in the offering were offered by ...
(Date:6/24/2016)... , June 24, 2016 The Academy of ... recommendations that would allow biopharmaceutical companies to ... entities that make formulary and coverage decisions, a move ... of new medicines. The recommendations address restrictions ... appear on the drug label, a prohibition that hinders ...
(Date:6/24/2016)... PUNE, India , June 24, 2016 ... "Pen Needles Market by Type (Standard Pen Needles, Safety ... 12mm), Therapy (Insulin, GLP-1, Growth Hormone), Mode of Purchase ... published by MarketsandMarkets, This report studies the market for ... is expected to reach USD 2.81 Billion by 2021 ...
Breaking Medicine Technology: